Gyre Therapeutics
GYRE
30 hedge funds and large institutions have $15M invested in Gyre Therapeutics in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.
6,840% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $15K
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
43% more funds holding
Funds holding: 21 → 30 (+9)
5% more capital invested
Capital invested by funds: $14.3M → $15M (+$734K)
0.4% more ownership
Funds ownership: 1.07% → 1.47% (+0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.5M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.36M |
| 3 |
State Street
Boston,
Massachusetts
|
+$762K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$501K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$317K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.05M |
| 2 |
Goldman Sachs
New York
|
-$806K |
| 3 |
Jane Street
New York
|
-$534K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$244K |
| 5 |
JP Morgan Chase
New York
|
-$234K |
GYRE Hedge Fund Activity: Q2 2024 in Review
30 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2024, worth a combined $15M — up 5.1% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GYRE positions and 7 closed out — a net gain of 9 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $4.5M. The largest seller was Millennium Management, exiting entirely with an estimated $1.05M sold.
- 30 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2024, up from 21 in Q1 2024.
- Funds reported $15M of Gyre Therapeutics stock for Q2 2024, up 5.1% quarter-over-quarter.
- 16 funds opened new Gyre Therapeutics positions in Q2 2024 and 7 closed out, a net change of +9 holders.
- The largest Gyre Therapeutics buyer in Q2 2024 was BlackRock, an estimated $4.5M added.
- The largest Gyre Therapeutics seller in Q2 2024 was Millennium Management, an estimated $1.05M sold.
Based on aggregated 13F filings for Q2 2024.